Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. They are building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science, and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement, and regenerative medicine.

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re  building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine. 

Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.

Newpath Management

Andreessen Horowitz

ARCH Venture Partners

Orbital Therapeutics

Orbital Therapeutics CSO, Dr. Gilles Besin, pictured here with Dr. Katalin Karikó, Nobel Prize Winner in Physiology or Medicine (2023), recently attended “Cracking the Code: The Dawn of Nucleic Acid Medicines” conference at Worcester Polytechnic Institute, where speakers discussed recent clinical successes, and current and upcoming challenges in the development of nucleic acid medicines! #CrackingTheCode23 #JoinOurOrbit

Do you have deep expertise successfully leading IND-enabling studies related to LNP/RNA? If so, there may be an available position open for you here at Orbital! Apply here to #JoinOurOrbit.

Congratulations to Orbital Co-Founder, Drew Weissman, on the 2023 Nobel Prize in Physiology or Medicine. Dr. Weissman and Katalin Karikó were jointly awarded the prize, “for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.” https://lnkd.in/g8-xG_b #JoinOurOrbit

We're excited to share that Orbital has been named as one of Biopharma's most promising startups in 2023! We're proud to be named to Endpoints 11. Congratulations, Orbiters! #JoinOurOrbit

Last week Orbital celebrated 1-year with a harbor cruise in San Francisco! Cheers to a great day and an even better year, Orbiters! #JoinOurOrbit

Kristen Ott's RNA Platform team here at Orbital is growing! We are looking for talented individuals with experience in both molecular biology and biochemistry to be a part of the design, production, and characterization of novel RNA molecules. Apply here! #JoinOurOrbit

Happy 1-year anniversary, Orbiters! It's been an exciting first year of defining new frontiers of science to lead the future of RNA medicines #JoinOurOrbit

With the combination of high caliber science, revolutionary technologies, a world-class team and an extraordinary team environment, Orbital is aiming to be a therapeutically transformational company. Check out some of our available openings below to #JoinOurOrbit!

https://lnkd.in/e5bfcMSy

Orbital’s CSO Gilles BESIN will be leading the discussion on Circular RNA, a RNA Platform for RNA Medicines at the mRNA Conference 2023 in Boston on August 28 – 29th! #JoinOurOrbit https://lnkd.in/eXyd4yPM

COM:ORBITALTX

Orbital Therapeutics

Analysis Not Available